In conversation with... Shun Lu
from Listen to The Lancet Hosted by The Lancet
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Listen to The Lancet?
This episode is 21 minutes long.
When was this Listen to The Lancet episode published?
This episode was published on October 19, 2025.
Can I download this Listen to The Lancet episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.